MEGHAN LUEBBERT: Open Payments
NPI 1023644994 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$892 in 39 payments from 11 companies in 2025. Trend: 2023 $320 · 2024 $712 · 2025 $892
Food & beverage: $892
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 17 | $244 |
| Collegium Pharmaceutical, Inc. | 6 | $176 |
| Axsome Therapeutics, Inc. | 3 | $161 |
| Vanda Pharmaceuticals Inc. | 5 | $158 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $43 |
| Janssen Pharmaceuticals, Inc | 1 | $22 |
| E.R. Squibb & Sons, L.L.C. | 1 | $20 |
| Tris Pharma Inc | 1 | $20 |
| Neurocrine BioSciences, Inc. | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
Products named: VRAYLAR, Jornay PM, Auvelity, FANAPT, CAPLYTA, HETLIOZ, SPRAVATO, COBENFY.
Industry payments across NE — which companies pay providers there.
